General Information of Drug (ID: DMHZJCG)

Drug Name
Pentamidine Drug Info
Synonyms
Lomidine; Nebupent; PENTAM; PNT; Pentacarinat; Pentamide; Pentamidin; Pentamidina; Pentamidinum; Pneumopent; PENTAMIDINE ISETHIONATE; Pentamidina [DCIT]; Pentamidine isetionate; Pentamidine mesylate; MB 800; Pentam 300; Lomidine (TN); MB-800; Nebupent (as isethionate); Pentacarinat (as isethionate); Pentam 300 (as isethionate); Pentamidine (INN); Pentamidinum [INN-Latin]; RP-2512; Nebupent (*Isethionate); Pentacarinat (*Isethionate); Pentam 300 (*Isethionate); Pentamidine Isethionate 2-Hydroxy-Ethanesulfonic Acid;Pentamidine [INN:BAN:DCF]; RP 2512 (*Isethionate); P,p'-(Pentamethylenedioxy)bis[benzamidine]; P,p'-(Pentamethylenedioxy)dibenzamidine; P,p'-(Pentamethylene-dioxy)bis-benzamidine; Benzenecarboximidamide, 4,4'-(1,5-pentanediylbis(oxy))bis-(9CI); 1,3-BIS(4-AMIDINOPHENOXY)PENTANE; 4, 4'-Diamidinodiphenoxypentane; 4,4'-(1,5-Pentanediylbis(oxy))bis-benzenecarboximidamide; 4,4'-(Pentamethylenedioxy)dibenzamide; 4,4'-(Pentamethylenedioxy)dibenzamidine; 4,4'-Diamidino-.alpha.,.omega.-diphenoxypentane; 4,4'-Diamidinodiphenoxypentane; 4,4'-[pentane-1,5-diylbis(oxy)]dibenzenecarboximidamide; 4-[5-(4-Carbamimidoylphenoxy)pentoxy]benzenecarboximidamide
Indication
Disease Entry ICD 11 Status REF
African trypanosomiasis 1F51 Approved [1]
Fungal infection 1F29-1F2F Approved [2]
Pneumocystis pneumonia CA40.20 Approved [1]
Human immunodeficiency virus infection 1C62 Withdrawn from market [3]
Therapeutic Class
Antifungal Agents
Cross-matching ID
PubChem CID
4735
ChEBI ID
CHEBI:45081
CAS Number
CAS 100-33-4
TTD Drug ID
DMHZJCG
VARIDT Drug ID
DR00085
INTEDE Drug ID
DR1252

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DTP
DME
DOT
Drug Status:
Approved Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Lactoferrin DMA7QTC Solid tumour/cancer 2A00-2F9Z Approved [4]
APC-2059 DM8IB6K Inflammatory bowel disease DD72 Discontinued in Phase 2 [13]
APC-366 DM02DNQ Asthma CA23 Discontinued in Phase 2 [4]
BABIM DM8AGOE Asthma CA23 Terminated [4]
BAY-17-1998 DM7LZFQ Asthma CA23 Terminated [14]
BAY-44-3428 DM40ORU Asthma CA23 Terminated [15]
Grassystatin a DM1PWX2 Discovery agent N.A. Investigative [16]
BMS-262084 DMETNA3 Discovery agent N.A. Investigative [17]
AMG-126737 DM9H7AZ Discovery agent N.A. Investigative [18]
MOL 6131 DMSF8UC Discovery agent N.A. Investigative [18]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [19]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [20]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [21]
Oxaliplatin DMQNWRD Adenocarcinoma 2D40 Approved [22]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [23]
Verapamil DMA7PEW Angina pectoris BA40 Approved [24]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [25]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [26]
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [27]
Propranolol DM79NTF Angina pectoris BA40 Approved [28]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [29]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [30]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [31]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [32]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [33]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [34]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [35]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [36]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [30]
Verapamil DMA7PEW Angina pectoris BA40 Approved [37]
Eplerenone DMF0NQR Heart failure BD10-BD13 Approved [79]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [80]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [81]
Voriconazole DMAOL2S Aspergillosis 1F20 Approved [82]
Proguanil DMBL79I Malaria 1F40-1F45 Approved [11]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [11]
Loratadine DMF3AN7 Allergy 4A80-4A85 Approved [83]
Nelfinavir mesylate DMFX6G8 N. A. N. A. Approved [84]
Capsaicin DMGMF6V Back pain ME84.Z Approved [85]
Axitinib DMGVH6N Renal cell carcinoma 2C90 Approved [86]
⏷ Show the Full List of 20 Drug(s)
Drug(s) Metabolized By Cytochrome P450 1A2 (CYP1A2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [38]
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [39]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [40]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [41]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [42]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [43]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [35]
Oxaliplatin DMQNWRD Adenocarcinoma 2D40 Approved [44]
Verapamil DMA7PEW Angina pectoris BA40 Approved [45]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [46]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 2D6 (CYP2D6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [47]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [48]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [49]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [33]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [37]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [50]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [51]
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [52]
Nicotine DMWX5CO Lung cancer 2C25.0 Approved [53]
Propranolol DM79NTF Angina pectoris BA40 Approved [54]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [87]
Paliperidone DM7NPJS Psychotic disorder 6A20-6A25 Approved [88]
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [89]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [90]
Oxatomide DM1F42Z Hay fever CA08.00 Approved [91]
Cinacalcet DMCX0K3 Hyperparathyroidism 5A51 Approved [92]
Capsaicin DMGMF6V Back pain ME84.Z Approved [93]
Quinidine DMLPICK N. A. N. A. Approved [94]
Buprenorphine DMPRI8G Opioid dependence 6C43.2Z Approved [95]
Methadone DMTW6IU Advanced cancer 2A00-2F9Z Approved [96]
⏷ Show the Full List of 20 Drug(s)
Drug(s) Metabolized By Cytochrome P450 3A5 (CYP3A5)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [55]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [56]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [57]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [58]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [59]
Sulfasalazine DMICA9H Irritable bowel syndrome DD91.0 Approved [60]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [61]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [62]
Verapamil DMA7PEW Angina pectoris BA40 Approved [63]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [58]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 2C8 (CYP2C8)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [38]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [64]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [64]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [65]
Verapamil DMA7PEW Angina pectoris BA40 Approved [66]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [67]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [68]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [64]
Mycophenolate mofetil DMPQAGE Hepatosplenic T-cell lymphoma Approved [69]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [70]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Mephenytoin 4-hydroxylase (CYP2C19)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Amoxicillin DMUYNEI Acute otitis media AB00 Approved [71]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [72]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [73]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [74]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [65]
Verapamil DMA7PEW Angina pectoris BA40 Approved [75]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [76]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [77]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [78]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [70]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 2C19 (CYP2C19)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [80]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [97]
Voriconazole DMAOL2S Aspergillosis 1F20 Approved [82]
Chloramphenicol DMFXEWT Bacterial infection 1A00-1C4Z Approved [98]
Capsaicin DMGMF6V Back pain ME84.Z Approved [93]
Stiripentol DMMSDOY Dravet syndrome 8A61.11 Approved [99]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [11]
Desipramine DMT2FDC Attention deficit hyperactivity disorder 6A05.Z Approved [97]
Amitriptyline DMK7F9S Depression 6A70-6A7Z Approved [100]
Clobazam - Lundbeck DMW1OQ0 Anxiety disorder 6B00-6B0Z Approved [101]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 2C9 (CYP2C9)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [80]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [102]
Dapsone DM4LT8A Acne vulgaris ED80 Approved [11]
Voriconazole DMAOL2S Aspergillosis 1F20 Approved [82]
Capsaicin DMGMF6V Back pain ME84.Z Approved [93]
Zafirlukast DMHNQOG Asthma CA23 Approved [103]
Niclosamide DMJAGXQ Cestodes infection 1F70-1F76 Approved [11]
Eicosapentaenoic acid/docosa-hexaenoic acid DMMUCG4 Hypertriglyceridemia 5C80.1 Approved [104]
Fluconazole DMOWZ6B Cryptococcal meningitis Approved [82]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [11]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Nuclear protein 1 (NUPR1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [105]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [8]
Ofloxacin DM0VQN3 Acute gonococcal cervicitis Approved [106]
Citalopram DM2G9AE Acute coronary syndrome BA41 Approved [107]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [8]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [8]
Quercetin DM3NC4M Obesity 5B81 Approved [108]
Fluoxetine DM3PD2C Bipolar depression Approved [8]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [109]
Erythromycin DM4K7GQ Acne vulgaris ED80 Approved [106]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [8]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [110]
Citalopram DM2G9AE Acute coronary syndrome BA41 Approved [107]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [8]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [8]
Rofecoxib DM3P5DA Osteoarthritis FA00-FA05 Approved [111]
Fluoxetine DM3PD2C Bipolar depression Approved [8]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [112]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [112]
Chlorpromazine DMBGZI3 Acute intermittent hepatic porphyria 5C58.11 Approved [8]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Serine protease hepsin (HPN)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [8]
Selenium DM25CGV N. A. N. A. Approved [113]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [8]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [8]
Quercetin DM3NC4M Obesity 5B81 Approved [108]
Fluoxetine DM3PD2C Bipolar depression Approved [8]
Erythromycin DM4K7GQ Acne vulgaris ED80 Approved [106]
Chlorpromazine DMBGZI3 Acute intermittent hepatic porphyria 5C58.11 Approved [8]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [114]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [115]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [8]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [116]
Citalopram DM2G9AE Acute coronary syndrome BA41 Approved [107]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [8]
Methotrexate DM2TEOL Anterior urethra cancer Approved [117]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [8]
Quercetin DM3NC4M Obesity 5B81 Approved [108]
Fluoxetine DM3PD2C Bipolar depression Approved [8]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [118]
Erythromycin DM4K7GQ Acne vulgaris ED80 Approved [106]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Asparagine synthetase (ASNS)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [119]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [8]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [120]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [8]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [121]
Methotrexate DM2TEOL Anterior urethra cancer Approved [122]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [106]
Fluoxetine DM3PD2C Bipolar depression Approved [8]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [123]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [124]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
2-deoxyglucose DMIAHVU Solid tumour/cancer 2A00-2F9Z Approved [125]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [126]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [8]
Citalopram DM2G9AE Acute coronary syndrome BA41 Approved [107]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [8]
Methotrexate DM2TEOL Anterior urethra cancer Approved [127]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [8]
Quercetin DM3NC4M Obesity 5B81 Approved [108]
Fluoxetine DM3PD2C Bipolar depression Approved [8]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [128]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Lanosterol synthase (LSS)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [8]
Clavulanate DM2FGRT Bacteremia 1A73 Approved [129]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [8]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [8]
Quercetin DM3NC4M Obesity 5B81 Approved [108]
Fluoxetine DM3PD2C Bipolar depression Approved [8]
obeticholic acid DM3Q1SM Primary biliary cholangitis DB96.1 Approved [130]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [131]
Erythromycin DM4K7GQ Acne vulgaris ED80 Approved [106]
Clarithromycin DM4M1SG Acute maxillary sinusitis Approved [8]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Inhibin beta E chain (INHBE)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [8]
Citalopram DM2G9AE Acute coronary syndrome BA41 Approved [107]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [8]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [8]
Quercetin DM3NC4M Obesity 5B81 Approved [108]
Fluoxetine DM3PD2C Bipolar depression Approved [8]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [131]
Erythromycin DM4K7GQ Acne vulgaris ED80 Approved [106]
Clarithromycin DM4M1SG Acute maxillary sinusitis Approved [8]
Panobinostat DM58WKG Chronic graft versus host disease Approved [132]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Calcipotriol DM03CP7 Psoriasis EA90 Approved [133]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [8]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [134]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [135]
Clavulanate DM2FGRT Bacteremia 1A73 Approved [129]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [8]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [106]
Deoxycholic acid DM3GYAL Subcutaneous fat disorder EF02 Approved [136]
Quercetin DM3NC4M Obesity 5B81 Approved [108]
Fluoxetine DM3PD2C Bipolar depression Approved [8]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [8]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [8]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [8]
Fluoxetine DM3PD2C Bipolar depression Approved [8]
Erythromycin DM4K7GQ Acne vulgaris ED80 Approved [106]
Chlorpromazine DMBGZI3 Acute intermittent hepatic porphyria 5C58.11 Approved [8]
Haloperidol DM96SE0 Delirium Approved [106]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [115]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [137]
Clozapine DMFC71L Schizophrenia 6A20 Approved [8]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Protein DEPP1 (DEPP1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [8]
Ofloxacin DM0VQN3 Acute gonococcal cervicitis Approved [106]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [138]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [8]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [8]
Quercetin DM3NC4M Obesity 5B81 Approved [108]
Fluoxetine DM3PD2C Bipolar depression Approved [8]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [139]
Erythromycin DM4K7GQ Acne vulgaris ED80 Approved [106]
Isoniazid DM5JVS3 Latent tuberculosis infection Approved [106]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Nibrin (NBN)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Quercetin DM3NC4M Obesity 5B81 Approved [108]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [124]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [140]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [141]
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [142]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [137]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [143]
Cupric Sulfate DMP0NFQ Fungal infection 1F29-1F2F Approved [144]
Decitabine DMQL8XJ Acute myelogenous leukaemia 2A41 Approved [145]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [146]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Interleukin-1 beta (IL1B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [147]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [138]
Gefitinib DM15F0X Colon adenocarcinoma Approved [148]
Fexofenadine DM17ONX Allergic rhinitis CA08.0 Approved [149]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [150]
Lumiracoxib DM1S4AG Chronic renal failure GB61.Z Approved [149]
Imiquimod DM1TMA3 Alopecia areata ED70.2 Approved [151]
Selenium DM25CGV N. A. N. A. Approved [152]
Ribavirin DMEYLH9 Hepatitis C virus infection 1E51.1 Approved [153]
Spironolactone DM2AQ5N Chronic heart failure BD1Z Approved [154]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Aspirin DM672AH Acute coronary syndrome BA41 Approved [155]
Carbamazepine DMZOLBI Epilepsy 8A60-8A68 Approved [156]
Amoxicillin DMUYNEI Acute otitis media AB00 Approved [156]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [157]
Allopurinol DMLPAOB Gout FA25 Approved [158]
Ticlopidine DMO946V Acute coronary syndrome BA41 Approved [159]
Selenium DM25CGV N. A. N. A. Approved [113]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [156]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [160]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [140]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [147]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [116]
Methotrexate DM2TEOL Anterior urethra cancer Approved [161]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [124]
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [162]
Leflunomide DMR8ONJ Arthritis FA20 Approved [163]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [164]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [137]
Clozapine DMFC71L Schizophrenia 6A20 Approved [165]
Zoledronate DMIXC7G Adenocarcinoma 2D40 Approved [166]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Histone H2AX (H2AX)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [167]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [168]
Selenium DM25CGV N. A. N. A. Approved [113]
Ribavirin DMEYLH9 Hepatitis C virus infection 1E51.1 Approved [169]
Etretinate DM2CZFA Keratosis ED56 Approved [170]
Methotrexate DM2TEOL Anterior urethra cancer Approved [171]
Dactinomycin DM2YGNW Adult kidney Wilms tumor Approved [172]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [173]
Lapatinib DM3BH1Y Breast cancer 2C60-2C65 Approved [174]
Quercetin DM3NC4M Obesity 5B81 Approved [175]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [176]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [116]
Quercetin DM3NC4M Obesity 5B81 Approved [108]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [115]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [177]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [143]
Cupric Sulfate DMP0NFQ Fungal infection 1F29-1F2F Approved [144]
Decitabine DMQL8XJ Acute myelogenous leukaemia 2A41 Approved [145]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [146]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [178]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metoclopramide DMFA5MY Nausea MD90 Approved [179]
Quinidine DMLPICK N. A. N. A. Approved [180]
Verapamil DMA7PEW Angina pectoris BA40 Approved [181]
Erythromycin DM4K7GQ Acne vulgaris ED80 Approved [182]
Clarithromycin DM4M1SG Acute maxillary sinusitis Approved [182]
Disopyramide DM5SYZP Long QT syndrome BC65.0 Approved [183]
Propranolol DM79NTF Angina pectoris BA40 Approved [184]
Amiodarone DMUTEX3 Tachyarrhythmias BC71 Approved [185]
Dofetilide DMPN1TW Sinus rhythm disorder BC9Y Approved [186]
Flecainide DMSQDLE Tachyarrhythmias BC71 Approved [182]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [187]
Paromomycin DM1AGXN Amoebiasis 1A36 Approved [188]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [189]
Etretinate DM2CZFA Keratosis ED56 Approved [190]
Quercetin DM3NC4M Obesity 5B81 Approved [191]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [139]
Remdesivir DMBFZ6L Coronavirus Disease 2019 (COVID-19) 1D6Y Approved [192]
Acetic Acid, Glacial DM4SJ5Y infection in the ear canal AA0Y Approved [193]
Rifampicin DM5DSFZ Non-insulin dependent diabetes 5A11 Approved [194]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [195]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 1B1 (CYP1B1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Flutamide DMK0O7U Prostate cancer 2C82.0 Approved [10]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [196]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [197]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [198]
Estrone DM5T6US Acne vulgaris ED80 Approved [199]
Melatonin DMKWFBT Depression 6A70-6A7Z Approved [200]
Vitamin A DMJ2AH4 Night blindness 9D45 Approved [201]
Amodiaquine DME4RA8 Malaria 1F40-1F45 Approved [202]
Daunorubicin DMQUSBT Acute monocytic leukemia Approved [203]
Pantothenic acid DM091H2 Vitamin deficiency 5B55-5B71 Approved [204]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tretinoin DM49DUI Acne vulgaris ED80 Approved [205]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [195]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [206]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [207]
Decitabine DMQL8XJ Acute myelogenous leukaemia 2A41 Approved [208]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [209]
Vorinostat DMWMPD4 Adult acute monocytic leukemia Approved [207]
Tamibarotene DM3G74J T-cell leukaemia 2A90 Phase 3 [205]
Resveratrol DM3RWXL Giant cell arteritis 4A44.2 Phase 3 [210]
TAK-243 DM4GKV2 Solid tumour/cancer 2A00-2F9Z Phase 1 [211]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Bile acid receptor (NR1H4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [135]
Nitrendipine DM21C09 Hypertension BA00-BA04 Approved [212]
Deoxycholic acid DM3GYAL Subcutaneous fat disorder EF02 Approved [213]
Quercetin DM3NC4M Obesity 5B81 Approved [108]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [214]
Nefazodone DM4ZS8M Major depressive disorder 6A70.3 Approved [215]
Nisoldipine DM7ISKJ Hypertension BA00-BA04 Approved [212]
Cholic Acid DM7OKQV Cholelithiasis DC11 Approved [213]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [9]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [115]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tryptase alpha/beta-1 (Tryptase) TTM1TDX TRYB1_HUMAN Inhibitor [4]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [5]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [6]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [6]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [7]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [6]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [6]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [6]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Alpha-1-antichymotrypsin (SERPINA3) OT9BP2S0 AACT_HUMAN Gene/Protein Processing [8]
Asparagine synthetase (ASNS) OT8R922G ASNS_HUMAN Gene/Protein Processing [8]
Bile acid receptor (NR1H4) OTWZLPTB NR1H4_HUMAN Gene/Protein Processing [9]
Cytochrome P450 1B1 (CYP1B1) OTYXFLSD CP1B1_HUMAN Gene/Protein Processing [10]
Cytochrome P450 2C19 (CYP2C19) OTFMJYYE CP2CJ_HUMAN Gene/Protein Processing [11]
Cytochrome P450 2C9 (CYP2C9) OTGLBN29 CP2C9_HUMAN Gene/Protein Processing [11]
Cytochrome P450 2D6 (CYP2D6) OTZJC802 CP2D6_HUMAN Gene/Protein Processing [11]
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Gene/Protein Processing [11]
Double-strand break repair protein MRE11 (MRE11) OTGU8TZM MRE11_HUMAN Gene/Protein Processing [12]
Fatty acid-binding protein, liver (FABP1) OTR34ETM FABPL_HUMAN Gene/Protein Processing [8]

References

1 Pentamidine FDA Label
2 Opportunities and challenges in antiparasitic drug discovery. Nat Rev Drug Discov. 2005 Sep;4(9):727-40.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 Inhibitors of tryptase for the treatment of mast cell-mediated diseases. Curr Pharm Des. 1998 Oct;4(5):381-96.
5 Transport of dicationic drugs pentamidine and furamidine by human organic cation transporters. Drug Metab Dispos. 2009 Feb;37(2):424-30.
6 Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42.
7 Value of preemptive CYP2C19 genotyping in allogeneic stem cell transplant patients considered for pentamidine administration. Clin Transplant. 2011 May-Jun;25(3):E271-5.
8 A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol Sci. 2005 Feb;83(2):282-92.
9 Investigation of imatinib and other approved drugs as starting points for antidiabetic drug discovery with FXR modulating activity. Biochem Pharmacol. 2012 Jun 15;83(12):1674-81. doi: 10.1016/j.bcp.2012.02.027. Epub 2012 Mar 7.
10 Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
11 Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
12 Bisbenzamidine derivative, pentamidine represses DNA damage response through inhibition of histone H2A acetylation. Mol Cancer. 2010 Feb 9;9:34. doi: 10.1186/1476-4598-9-34.
13 Treatment of mildly to moderately active ulcerative colitis with a tryptase inhibitor (APC 2059): an open-label pilot study. Aliment Pharmacol Ther. 2002 Mar;16(3):407-13.
14 Bayer AG to Develop Arris Asthma Compound; Arris to Receive Milestone Payment. 1996 Business Wire
15 Bayer AG to Develop Arris Asthma Compound; Arris to Receive Milestone Payment. 1996 Business Wire
16 Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation. J Med Chem. 2009 Sep 24;52(18):5732-47.
17 Synthesis and SAR of 4-carboxy-2-azetidinone mechanism-based tryptase inhibitors. Bioorg Med Chem Lett. 2002 Nov 4;12(21):3229-33.
18 Tryptase inhibition blocks airway inflammation in a mouse asthma model. J Immunol. 2002 Feb 15;168(4):1992-2000.
19 Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30.
20 Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006 Nov;319(2):879-86.
21 Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):639-42.
22 Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006 Sep 1;66(17):8847-57.
23 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
24 Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
25 Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma
26 Comparison of type I and type II organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001 Jul;298(1):110-5.
27 Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.
28 Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
29 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
30 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
31 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
32 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
33 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
34 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
35 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
36 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
37 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
38 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
39 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
40 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
41 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
42 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
43 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
44 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
45 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
46 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
47 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
48 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
49 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
50 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
51 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
52 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
53 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
54 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
55 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
56 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
57 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
58 Drug Interactions Flockhart Table
59 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
60 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
61 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
62 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
63 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
64 Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
65 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
66 Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
67 Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
68 Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
69 PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
70 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
71 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
72 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
73 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
74 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
75 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
76 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
77 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
78 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
79 The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism. Toxicol Lett. 2019 Oct 15;315:9-13.
80 Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. Chem Biol Interact. 2014 May 25;215:62-8.
81 Retinoids activate the RXR/SXR-mediated pathway and induce the endogenous CYP3A4 activity in Huh7 human hepatoma cells. Toxicol Sci. 2006 Jul;92(1):51-60.
82 The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
83 Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5591-4.
84 Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther. 2005 Feb;312(2):583-91.
85 Studies of the toxicological potential of capsinoids, XIII: inhibitory effects of capsaicin and capsinoids on cytochrome P450 3A4 in human liver microsomes. Int J Toxicol. 2010 Mar;29(2 Suppl):22S-6S.
86 Investigation of the effects of axitinib on the pharmacokinetics of loperamide and its main metabolite N-demethylated loperamide in rats by UPLC-MS/MS. Chem Biol Interact. 2019 Sep 1;310:108744. doi: 10.1016/j.cbi.2019.108744. Epub 2019 Jul 9.
87 Human recombinant cytochrome P450 enzymes display distinct hydrogen peroxide generating activities during substrate independent NADPH oxidase reactions. Toxicol Sci. 2014 Oct;141(2):344-52. doi: 10.1093/toxsci/kfu133. Epub 2014 Jul 24.
88 Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl). 1999 Dec;147(3):300-5. doi: 10.1007/s002130051171.
89 Effect of penicillin-based antibiotics, amoxicillin, ampicillin, and piperacillin, on drug-metabolizing activities of human hepatic cytochromes P450. J Toxicol Sci. 2016 Feb;41(1):143-6.
90 Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6. Drug Metab Dispos. 2011 Nov;39(11):2049-56. doi: 10.1124/dmd.111.041384. Epub 2011 Aug 5.
91 Identification of human P450 isoforms involved in the metabolism of the antiallergic drug, oxatomide, and its kinetic parameters and inhibition constants. Biol Pharm Bull. 2005 Feb;28(2):328-34.
92 Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl. Eur J Clin Pharmacol. 2007 Feb;63(2):159-63.
93 Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 2012;14(4):382-95.
94 Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Clin Pharmacol Ther. 2001 Oct;70(4):327-35.
95 Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro. Drug Metab Dispos. 2003 Jun;31(6):768-72.
96 Expression, purification, and characterization of mouse CYP2d22. Drug Metab Dispos. 2006 Jul;34(7):1167-74.
97 Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors. Chem Biol Interact. 2004 Apr 15;147(3):331-40.
98 Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class. Toxicol Lett. 2016 Jan 22;241:82-94.
99 Stiripentol. Expert Opin Investig Drugs. 2005 Jul;14(7):905-11.
100 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
101 In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19. Drug Metab Dispos. 2004 Nov;32(11):1279-86.
102 Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab Dispos. 2003 Apr;31(4):439-46.
103 Potential of pranlukast and zafirlukast in the inhibition of human liver cytochrome P450 enzymes. Xenobiotica. 2004 May;34(5):429-38.
104 The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes. Life Sci. 2006 Nov 25;79(26):2432-40.
105 Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
106 Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells. Toxicol Sci. 2007 Mar;96(1):101-14.
107 In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipid based methodologies. Toxicol Sci. 2007 Sep;99(1):162-73.
108 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
109 Effect of retinoic acid on gene expression in human conjunctival epithelium: secretory phospholipase A2 mediates retinoic acid induction of MUC16. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4050-61.
110 Oxidative Stress Alters miRNA and Gene Expression Profiles in Villous First Trimester Trophoblasts. Biomed Res Int. 2015;2015:257090. doi: 10.1155/2015/257090. Epub 2015 Aug 3.
111 Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain. Pain. 2007 Mar;128(1-2):136-47.
112 Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.
113 Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
114 Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
115 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
116 Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
117 The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
118 Species-specific toxicity of diclofenac and troglitazone in primary human and rat hepatocytes. Chem Biol Interact. 2009 Apr 15;179(1):17-24.
119 Inhibiting Heat Shock Proteins Can Potentiate the Cytotoxic Effect of Cannabidiol in Human Glioma Cells. Anticancer Res. 2015 Nov;35(11):5827-37.
120 Comparative gene expression profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in human breast cancer cells. J Cell Biochem. 2006 Aug 1;98(5):1163-84.
121 Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
122 Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
123 Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
124 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
125 Kinetic analysis of the liver-type (GLUT2) and brain-type (GLUT3) glucose transporters in Xenopus oocytes: substrate specificities and effects of transport inhibitors. Biochem J. 1993 Mar 15;290 ( Pt 3)(Pt 3):701-6. doi: 10.1042/bj2900701.
126 Cannabidiol induces antioxidant pathways in keratinocytes by targeting BACH1. Redox Biol. 2020 Jan;28:101321. doi: 10.1016/j.redox.2019.101321. Epub 2019 Sep 5.
127 Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
128 Retinoic acid represses a cassette of candidate pluripotency chromosome 12p genes during induced loss of human embryonal carcinoma tumorigenicity. Biochim Biophys Acta. 2005 Oct 15;1731(1):48-56. doi: 10.1016/j.bbaexp.2005.08.006. Epub 2005 Sep 1.
129 Molecular mechanisms of hepatotoxic cholestasis by clavulanic acid: Role of NRF2 and FXR pathways. Food Chem Toxicol. 2021 Dec;158:112664. doi: 10.1016/j.fct.2021.112664. Epub 2021 Nov 9.
130 Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
131 Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
132 A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
133 Adaptive homeostasis of the vitamin D-vitamin D nuclear receptor axis in 8-methoxypsoralen-induced hepatotoxicity. Toxicol Appl Pharmacol. 2019 Jan 1;362:150-158. doi: 10.1016/j.taap.2018.11.002. Epub 2018 Nov 10.
134 Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
135 Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach. Toxicology. 2013 Apr 5;306:24-34.
136 Farnesoid X receptor induces murine scavenger receptor Class B type I via intron binding. PLoS One. 2012;7(4):e35895. doi: 10.1371/journal.pone.0035895. Epub 2012 Apr 23.
137 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
138 ERE-independent ERalpha target genes differentially expressed in human breast tumors. Mol Cell Endocrinol. 2005 Dec 21;245(1-2):53-9. doi: 10.1016/j.mce.2005.10.003. Epub 2005 Nov 17.
139 Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
140 Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
141 Arsenic trioxide induces different gene expression profiles of genes related to growth and apoptosis in glioma cells dependent on the p53 status. Mol Biol Rep. 2008 Sep;35(3):421-9.
142 Epigenetic activation of O-linked -N-acetylglucosamine transferase overrides the differentiation blockage in acute leukemia. EBioMedicine. 2020 Apr;54:102678. doi: 10.1016/j.ebiom.2020.102678. Epub 2020 Apr 6.
143 Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
144 Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
145 DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. Mol Cell Biol. 2008 Jan;28(2):752-71. doi: 10.1128/MCB.01799-07. Epub 2007 Nov 8.
146 Deletion of NAD(P)H:quinone oxidoreductase 1 represses Mre11-Rad50-Nbs1 complex protein expression in cisplatin-induced nephrotoxicity. Toxicol Lett. 2016 Jan 22;243:22-30.
147 Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.
148 Reactive metabolite of gefitinib activates inflammasomes: implications for gefitinib-induced idiosyncratic reaction. J Toxicol Sci. 2020;45(11):673-680. doi: 10.2131/jts.45.673.
149 An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
150 Gypenosides protect retinal pigment epithelium cells from oxidative stress. Food Chem Toxicol. 2018 Feb;112:76-85.
151 (9)-Tetrahydrocannabinol Suppresses Monocyte-Mediated Astrocyte Production of Monocyte Chemoattractant Protein 1 and Interleukin-6 in a Toll-Like Receptor 7-Stimulated Human Coculture. J Pharmacol Exp Ther. 2019 Oct;371(1):191-201. doi: 10.1124/jpet.119.260661. Epub 2019 Aug 5.
152 Changes in gene expression profiles in response to selenium supplementation among individuals with arsenic-induced pre-malignant skin lesions. Toxicol Lett. 2007 Mar 8;169(2):162-76. doi: 10.1016/j.toxlet.2007.01.006. Epub 2007 Jan 19.
153 Profiling the immunotoxicity of chemicals based on in vitro evaluation by a combination of the Multi-ImmunoTox assay and the IL-8 Luc assay. Arch Toxicol. 2018 Jun;92(6):2043-2054. doi: 10.1007/s00204-018-2199-7. Epub 2018 Mar 29.
154 Spironolactone induces apoptosis in human mononuclear cells. Association between apoptosis and cytokine suppression. Apoptosis. 2006 Apr;11(4):573-9. doi: 10.1007/s10495-006-4919-3.
155 The human leucocyte antigen-DRB1*1302-DQB1*0609-DPB1*0201 haplotype may be a strong genetic marker for aspirin-induced urticaria. Clin Exp Allergy. 2005 Mar;35(3):339-44. doi: 10.1111/j.1365-2222.2004.02197.x.
156 Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
157 Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
158 A study of HLA class I and class II 4-digit allele level in Stevens-Johnson syndrome and toxic epidermal necrolysis. Int J Immunogenet. 2011 Aug;38(4):303-9. doi: 10.1111/j.1744-313X.2011.01011.x. Epub 2011 May 4.
159 Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study. Pharmacogenomics J. 2008 Feb;8(1):29-33. doi: 10.1038/sj.tpj.6500442. Epub 2007 Mar 6.
160 Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers. Clin Breast Cancer. 2013 Oct;13(5):401-8.
161 Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
162 THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
163 Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
164 Evaluation of a human iPSC-derived BBB model for repeated dose toxicity testing with cyclosporine A as model compound. Toxicol In Vitro. 2021 Jun;73:105112. doi: 10.1016/j.tiv.2021.105112. Epub 2021 Feb 22.
165 Toxicoproteomics reveals an effect of clozapine on autophagy in human liver spheroids. Toxicol Mech Methods. 2023 Jun;33(5):401-410. doi: 10.1080/15376516.2022.2156005. Epub 2022 Dec 19.
166 Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
167 Cannabinoids synergize with carfilzomib, reducing multiple myeloma cells viability and migration. Oncotarget. 2016 Nov 22;7(47):77543-77557. doi: 10.18632/oncotarget.12721.
168 Hsa-let-7g miRNA regulates the anti-tumor effects of gastric cancer cells under oxidative stress through the expression of DDR genes. J Toxicol Sci. 2015 Jun;40(3):329-38. doi: 10.2131/jts.40.329.
169 Inhibition of cardiomyocyte differentiation of human induced pluripotent stem cells by Ribavirin: Implication for its cardiac developmental toxicity. Toxicology. 2020 Apr 15;435:152422. doi: 10.1016/j.tox.2020.152422. Epub 2020 Feb 26.
170 Synthesis and structure-activity relationships of new antiproliferative and proapoptotic retinoid-related biphenyl-4-yl-acrylic acids. Bioorg Med Chem. 2007 Jul 15;15(14):4863-75. doi: 10.1016/j.bmc.2007.04.057. Epub 2007 May 3.
171 Methotrexate induces apoptosis through p53/p21-dependent pathway and increases E-cadherin expression through downregulation of HDAC/EZH2. Biochem Pharmacol. 2011 Feb 15;81(4):510-7. doi: 10.1016/j.bcp.2010.11.014. Epub 2010 Nov 27.
172 Actinomycin D inhibits the expression of the cystine/glutamate transporter xCT via attenuation of CD133 synthesis in CD133(+) HCC. Chem Biol Interact. 2019 Aug 25;309:108713. doi: 10.1016/j.cbi.2019.06.026. Epub 2019 Jun 19.
173 Simvastatin and purine analogs have a synergic effect on apoptosis of chronic lymphocytic leukemia cells. Ann Hematol. 2010 Nov;89(11):1115-24. doi: 10.1007/s00277-010-0988-z. Epub 2010 May 25.
174 The involvement of hepatic cytochrome P450s in the cytotoxicity of lapatinib. Toxicol Sci. 2023 Dec 21;197(1):69-78. doi: 10.1093/toxsci/kfad099.
175 The isoflavonoids genistein and quercetin activate different stress signaling pathways as shown by analysis of site-specific phosphorylation of ATM, p53 and histone H2AX. DNA Repair (Amst). 2004 Mar 4;3(3):235-44. doi: 10.1016/j.dnarep.2003.10.014.
176 Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells. Toxicol Sci. 2023 Feb 17;191(2):227-238. doi: 10.1093/toxsci/kfac131.
177 Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
178 Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
179 Comparison of the effects of metoclopramide and domperidone on HERG channels. Pharmacology. 2005 Apr;74(1):31-6. doi: 10.1159/000083234. Epub 2005 Jan 7.
180 Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol. 2005 Jan;16(1):54-8. doi: 10.1046/j.1540-8167.2005.04470.x.
181 Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds. Assay Drug Dev Technol. 2004 Oct;2(5):497-506. doi: 10.1089/adt.2004.2.497.
182 Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. Toxicol Sci. 2013 Dec;136(2):581-94. doi: 10.1093/toxsci/kft205. Epub 2013 Sep 19.
183 Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs. Br J Pharmacol. 2008 Nov;155(6):957-66. doi: 10.1038/bjp.2008.325. Epub 2008 Aug 25.
184 Comparison of HERG channel blocking effects of various beta-blockers-- implication for clinical strategy. Br J Pharmacol. 2006 Mar;147(6):642-52. doi: 10.1038/sj.bjp.0706508.
185 Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels. Naunyn Schmiedebergs Arch Pharmacol. 1999 Mar;359(3):212-9. doi: 10.1007/pl00005344.
186 Redox state dependency of HERGS631C channel pharmacology: relation to C-type inactivation. FEBS Lett. 2000 May 26;474(1):111-5. doi: 10.1016/s0014-5793(00)01586-6.
187 Cannabidiol Induces Cell Cycle Arrest and Cell Apoptosis in Human Gastric Cancer SGC-7901 Cells. Biomolecules. 2019 Jul 25;9(8):302. doi: 10.3390/biom9080302.
188 Correction of ATM gene function by aminoglycoside-induced read-through of premature termination codons. Proc Natl Acad Sci U S A. 2004 Nov 2;101(44):15676-81. doi: 10.1073/pnas.0405155101. Epub 2004 Oct 21.
189 Pro-oxidant induced DNA damage in human lymphoblastoid cells: homeostatic mechanisms of genotoxic tolerance. Toxicol Sci. 2012 Aug;128(2):387-97. doi: 10.1093/toxsci/kfs152. Epub 2012 Apr 26.
190 Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma. Br J Dermatol. 2009 Mar;160(3):519-26. doi: 10.1111/j.1365-2133.2008.08931.x. Epub 2008 Nov 25.
191 Multifaceted preventive effects of single agent quercetin on a human prostate adenocarcinoma cell line (PC-3): implications for nutritional transcriptomics and multi-target therapy. Med Oncol. 2011 Dec;28(4):1395-404. doi: 10.1007/s12032-010-9603-3. Epub 2010 Jul 2.
192 An in vitro study on anti-carcinogenic effect of remdesivir in human ovarian cancer cells via generation of reactive oxygen species. Hum Exp Toxicol. 2022 Jan-Dec;41:9603271221089257. doi: 10.1177/09603271221089257.
193 Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res. 2005 Dec 15;65(24):11676-88.
194 Integrated analysis of rifampicin-induced microRNA and gene expression changes in human hepatocytes. Drug Metab Pharmacokinet. 2014;29(4):333-40.
195 Arsenic trioxide induces apoptosis in NB-4, an acute promyelocytic leukemia cell line, through up-regulation of p73 via suppression of nuclear factor kappa B-mediated inhibition of p73 transcription and prevention of NF-kappaB-mediated induction of XIAP, cIAP2, BCL-XL and survivin. Med Oncol. 2010 Sep;27(3):833-42. doi: 10.1007/s12032-009-9294-9. Epub 2009 Sep 10.
196 Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
197 Convergent transcriptional profiles induced by endogenous estrogen and distinct xenoestrogens in breast cancer cells. Carcinogenesis. 2006 Aug;27(8):1567-78.
198 Gene expression in endometrial cancer cells (Ishikawa) after short time high dose exposure to progesterone. Steroids. 2008 Jan;73(1):116-28.
199 In vitro aromatic bioactivation of the weak estrogen E(2)alpha and genesis of DNA adducts. Steroids. 2005 Mar;70(3):161-72. doi: 10.1016/j.steroids.2004.11.004.
200 Metabolism of melatonin by human cytochromes p450. Drug Metab Dispos. 2005 Apr;33(4):489-94.
201 Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1b1. Drug Metab Dispos. 2004 Aug;32(8):840-7.
202 Apoptosis contributes to the cytotoxicity induced by amodiaquine and its major metabolite N-desethylamodiaquine in hepatic cells. Toxicol In Vitro. 2020 Feb;62:104669. doi: 10.1016/j.tiv.2019.104669. Epub 2019 Oct 16.
203 Genetic variants contributing to daunorubicin-induced cytotoxicity. Cancer Res. 2008 May 1;68(9):3161-8. doi: 10.1158/0008-5472.CAN-07-6381.
204 Calcium pantothenate modulates gene expression in proliferating human dermal fibroblasts. Exp Dermatol. 2009 Nov;18(11):969-78. doi: 10.1111/j.1600-0625.2009.00884.x. Epub 2009 Apr 8.
205 Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
206 Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
207 A genomic approach to predict synergistic combinations for breast cancer treatment. Pharmacogenomics J. 2013 Feb;13(1):94-104. doi: 10.1038/tpj.2011.48. Epub 2011 Nov 15.
208 Gene induction and apoptosis in human hepatocellular carci-noma cells SMMC-7721 exposed to 5-aza-2'-deoxycytidine. Chin Med J (Engl). 2007 Sep 20;120(18):1626-31.
209 Acetylation and phosphorylation of SRSF2 control cell fate decision in response to cisplatin. EMBO J. 2011 Feb 2;30(3):510-23. doi: 10.1038/emboj.2010.333. Epub 2010 Dec 14.
210 A human tRNA synthetase is a potent PARP1-activating effector target for resveratrol. Nature. 2015 Mar 19;519(7543):370-3. doi: 10.1038/nature14028. Epub 2014 Dec 22.
211 Inhibiting ubiquitination causes an accumulation of SUMOylated newly synthesized nuclear proteins at PML bodies. J Biol Chem. 2019 Oct 18;294(42):15218-15234. doi: 10.1074/jbc.RA119.009147. Epub 2019 Jul 8.
212 Quantitative high-throughput profiling of environmental chemicals and drugs that modulate farnesoid X receptor. Sci Rep. 2014 Sep 26;4:6437. doi: 10.1038/srep06437.
213 Potency of individual bile acids to regulate bile acid synthesis and transport genes in primary human hepatocyte cultures. Toxicol Sci. 2014 Oct;141(2):538-46. doi: 10.1093/toxsci/kfu151. Epub 2014 Jul 23.
214 The farnesoid X receptor FXRalpha/NR1H4 acquired ligand specificity for bile salts late in vertebrate evolution. Am J Physiol Regul Integr Comp Physiol. 2007 Sep;293(3):R1400-9. doi: 10.1152/ajpregu.00781.2006. Epub 2007 Jun 13.
215 Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury. Arch Toxicol. 2020 Apr;94(4):1151-1172. doi: 10.1007/s00204-020-02691-9. Epub 2020 Mar 10.